| 11 |
Outcome of Anthracycline versus Taxane Based Regimens on Different Metastatic Sites in Breast Cancer |
2024 |
| 12 |
Prognostic Value of Erythropoietin-Producing Hepatocellular Receptor A2 (Epha2) Serum Marker in Colorectal Cancer |
2024 |
| 13 |
Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line |
2024 |
| 14 |
The transcription factor ZEB-1 conveys chemoresistance in breast cancer |
2024 |
| 15 |
CD44 as a prognostic marker in early colorectal cancer: single center experience “South Egypt cancer institute”, Egypt |
2023 |
| 16 |
FOXP3 Expression as a Biomarker in Metastatic Colorectal Cancer Treated with Irinotecan-based Therapy |
2023 |
| 17 |
Tumor Lymphocytic Infiltration as a Prognostic Factor in Gastric Carcinoma |
2023 |
| 18 |
Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents |
2021 |
| 19 |
Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents |
2021 |
| 20 |
Assessment of the clinical value of red cell distribution width in patients with de novo hepatocellular carcinoma following HCV clearance with the direct-acting antiviral agents |
2021 |
